Spyre Therapeutics Inc (NAS:SYRE)

$ 35.92 0.79 (2.25%) Market Cap: 1.83 Bil Enterprise Value: 1.63 Bil PE Ratio: 0 PB Ratio: 8.35 GF Score: 51/100

Aeglea Bio Therapeutics Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 07, 2023
Aeglea Bio Therapeutics Inc at Stifel Immunology and Inflammation Virtual Summit Transcript
Sep 20, 2023
Aeglea Bio Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 06, 2023
Aeglea Bio Therapeutics Inc KOL Webinar on Classical Homocystinuria and Pegtarviliase Call Transcript
Oct 27, 2022
Aeglea Bio Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 07, 2022
Aeglea Bio Therapeutics Inc KOL and Patient Caregiver Webinar on Arginase 1 Deficiency - Corporate Call Transcript
Feb 03, 2022
Aeglea Bio Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Aeglea Bio Therapeutics Inc Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency Call Transcript
Dec 06, 2021
Aeglea Bio Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 08, 2021
Aeglea Bio Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Aeglea Bio Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 08, 2020
Aeglea Bio Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Aeglea Bio Therapeutics Inc to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium - Conference Call Transcript
Sep 03, 2019
Aeglea BioTherapeutics, Inc. - Special Call Transcript
Apr 08, 2019
Q4 2018 Aeglea Bio Therapeutics Inc Earnings Call Transcript
Mar 07, 2019

$205 (+1.74%)

Earnings

Aeglea Bio Therapeutics Inc Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency Call Transcript

Dec 06, 2021 / 01:00PM GMT

Release Date Price: $95.25 (-36.50%)

Transcript

Operator

Greetings, and welcome to the Aeglea BioTherapeutics PEACE Phase III Topline Study Results. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Kelly Boothe, Head of Corporate Communications and Investor Relations for Aeglea BioTherapeutics. Thank you. You may begin.

Kelly Boothe

Aeglea BioTherapeutics, Inc. - Senior Director of Corporate Communications & IR

Thank you, operator, and good morning, everyone. Joining me on today's call to discuss the PEACE Phase III topline results are Dr. Anthony Quinn, Chief Executive Officer; Dr. Eric Bradford, Chief Development Officer; Michael Hanley, Chief Commercial Officer; Dr. Leslie Sloan, Chief Operating Officer; and Jonathan Alspaugh, Chief Financial Officer.

The Form 8-K with our press release was filed this morning and is available on the SEC's EDGAR system and on our website. I would like to remind you that various remarks that we make on this call include forward-looking statements for the purposes of the safe harbor

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.